Feb.20 PM | The immune system as vector and target |
Discussion leader: E. Vitetta
Jacques Banchereau, Baylor Institute for Immunology Research
"Dendritic cells as vectors and targets for immunotherapy"
Randolph J. Noelle, Dartmouth University
"Immunosuppression of cell-mediated immunity by anti-CD154"
Albert Zlotnik, DNAX Research Institute
"Nature's own drug delivery: lessons from the chemokine superfamily"
Feb 21 AM | Normal and pathologic physiology and their impact on drug delivery |
Discussion leader: P. Thorpe
Rakesh Jain, Harvard Medical School
"Role of physiology in drug delivery into tumors"
Eng Lo, Harvard Medical School
"Limitations of drug delivery into damaged brain"
Robert Kimberly, University of Alabama School of Medicine
"Endogenous immunoglobulin receptors: natural variants and implications for Ig-based biologics"
Feb. 21 PM | Tumor targeting I |
Discussion leader: J. Banchereau
Susanna Rybak, National Cancer Institute
"Novel biological delivery of RNA damaging agents for cancer therapy"
Barbara Pedley, Royal Free and University College Medical School, London
"A combined antibody and antivascular approach for enhanced cancer therapy"
Peter Senter, Seattle Genetics, Inc.
"Anticancer prodrug activation by targeted enzymes"
Feb. 22 AM | Tumor targeting II |
Discussion leader: L. Leserman
Terry Allen, University of Alberta
"Intracellular trafficking of doxorubicin"
David Needham, Duke University
"Mechanochemistry of lipid vesicles: implications for drug release"
Ellen Vitetta, University of Texas Southwestern Medical Center
"Immunotoxins 2000: from bedside to bench"
Eric Sievers, Fred Hutchinson Cancer Research Center
"Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy"
Feb. 22 PM | Angiogenesis and vascular targeting |
Discussion leader: P. Trail
Peter Bohlen, ImClone Systems, Inc.
"Monoclonal antibodies to the VEGF receptor"
Renata Pasqualini, University of Texas, M.D. Anderson Cancer Center
"Vascular targeting"
Sophia Ran, University of Texas Southwestern Medical School
"Tumor-restricted thrombosis"
Feb. 23 AM | Novel carriers and delivery systems |
Discussion leader: V. Torchilin
Steven F. Dowdy, Howard Hughes Medical Institute, Washington University School of Medicine
"Protein transduction: delivery of biologically active protein into cells in vivo"
Andy Janoff, The Liposome Company, Inc.
"Novel modular fusogenic delivery systems for condensed plasmid DNA"
Jonathan Schneck, Johns Hopkins University School of Medicine
"MHC-based diagnostics and therapeutics: clinical applications for immune-mediated diseases"
Jindrich Kopecek, University of Utah
"New targeting strategies: polymerizable antibody fragments and synthetic epitopes"
Afternoon: Excursion. Whale watching and/or Getty Museum
Feb. 23 PM | Selected short presentations |
Discussion leaders: L. Leserman and P. Trail
Feb. 24 AM | Pharmacology and biology of gene therapy |
Discussion leader: F. Szoka
E. Antonio Chiocca, Harvard Medical School
"Interactions between the innate immune system and oncolytic viruses:
a hurdle for effective gene therapy of tumors"
Theodore Friedmann, University of California at San Diego
"Human gene therapy"
Muthiah Manoharan, Isis Pharmaceuticals
"Designer antisense oligonucleotide constructs"
Ivan King, VION Pharmaceuticals, Inc.
"Avirulent Salmonella typhimurium as a cancer-selective gene delivery vector"
Jean-Paul Behr, CNRS/Université Louis Pasteur de Strasbourg
"Intracellular trafficking of gene constructs"
Feb. 24 PM | Clinical developments |
Discussion leader: Andy Janoff
Louis Weiner, Fox Chase Cancer Center
"Antibody-based fusion proteins as platforms for cancer therapy"
Mark Pegram, UCLA School of Medicine
"Targeted biological therapy for metastatic breast cancer"
Jacques Barbet, Université de la Mediterranée, Marseille
"Pretargeted radioimmunotherapy of solid tumors"
|